HER2-Positive Breast Cancer

September 16, 2020

Breast cancer is the most common cancer that affects women, with estimates that it will account for 30% of all new cancer diagnoses in women in 2020. As the most commonly overexpressed receptor in breast cancer, HER2 is amplified or overexpressed in about 15% of breast cancers, leading to dysregulated cell proliferation. This article explores the current breast cancer landscape, with a focus on emerging HER2-targeted therapies, and discusses the unmet needs within the treatment landscape.

September 16, 2020

Sara M. Tolaney, MD, MPH speaks to the testing and treatment advances for women with HER2-positive breast cancer.

September 11, 2020

Experts in breast oncology review 3 clinical cases of HER2+ breast cancer and discuss individualized treatment approaches for each patient.

August 27, 2020

Frontline trastuzumab plus lapatinib and an aromatase inhibitor demonstrated superior progression-free survival compared with the trastuzumab/aromatase inhibitor alone as treatment of patients with HER2-positive, HR-positive metastatic breast cancer.

August 20, 2020

In an interview with Targeted Oncology following the conference, Kevin Kalinsky, MD, MS, gave his take on how targeted therapies are impacting the field of HER2-positive metastatic breast cancer, and he interprets the primary data from the phase 2 HER2CLIMB trial.

August 14, 2020

In an interview with Targeted Oncology, Stephanie Weiss, MD, reviewed the treatment landscape for HER2-positive metastatic breast cancer and gave her predictions on how the paradigm will evolve for patients with brain metastases now that tucatinib has demonstrated efficacy.

August 14, 2020

Multiple positive responses were observed in an exploratory efficacy analysis evaluating tucatinib in combination with trastuzumab and capecitabine in patients with previously treated HER2-positive metastatic breast cancer with brain metastases in the previously reported HER2CLIMB trial.

August 14, 2020

In an interview with Targeted Oncology following the SNO Brain Metastasis Meeting, Nancy Lin, MD, discussed the treatment of brain metastases in HER2-positive metastatic breast cancer in general, as well as the subgroup analysis of patients with brain metastases in the phase 2 HER2CLIMB clinical trial.

August 12, 2020

Julie Gralow, MD, discusses the primary analysis of trastuzumab emtansine plus pertuzumab versus trastuzumab, pertuzumab, and taxane, after anthracyclines as adjuvant therapy in patients with high-risk HER2-positive early breast cancer in the of the KAITLIN study.

July 31, 2020

Experts from Sarah Cannon Research Institute talk about the expanding role of targeted treatment options in early HER2+ breast cancer.